These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Phosphorylated α-synuclein and phosphorylated tau-protein in sural nerves may contribute to differentiate Parkinson's disease from multiple system atrophy and progressive supranuclear paralysis. Rong Z; Shen F; Wang Y; Sun L; Wu J; Zhang H; Yuan Y; Jiang W; Li X; Ji P; Zhang K Neurosci Lett; 2021 Jun; 756():135964. PubMed ID: 34022266 [TBL] [Abstract][Full Text] [Related]
3. Salivary alpha-synuclein in the diagnosis of Parkinson's disease and Progressive Supranuclear Palsy. Vivacqua G; Suppa A; Mancinelli R; Belvisi D; Fabbrini A; Costanzo M; Formica A; Onori P; Fabbrini G; Berardelli A Parkinsonism Relat Disord; 2019 Jun; 63():143-148. PubMed ID: 30796010 [TBL] [Abstract][Full Text] [Related]
4. The evolution of diagnosis from symptom onset to death in progressive supranuclear palsy (PSP) and corticobasal degeneration (CBD) compared to Parkinson's disease (PD). Swallow DMA; Counsell CE J Neurol; 2023 Jul; 270(7):3464-3474. PubMed ID: 36971841 [TBL] [Abstract][Full Text] [Related]
5. Post mortem cerebrospinal fluid α-synuclein levels are raised in multiple system atrophy and distinguish this from the other α-synucleinopathies, Parkinson's disease and Dementia with Lewy bodies. Foulds PG; Yokota O; Thurston A; Davidson Y; Ahmed Z; Holton J; Thompson JC; Akiyama H; Arai T; Hasegawa M; Gerhard A; Allsop D; Mann DM Neurobiol Dis; 2012 Jan; 45(1):188-95. PubMed ID: 21856424 [TBL] [Abstract][Full Text] [Related]
6. A panel of nine cerebrospinal fluid biomarkers may identify patients with atypical parkinsonian syndromes. Magdalinou NK; Paterson RW; Schott JM; Fox NC; Mummery C; Blennow K; Bhatia K; Morris HR; Giunti P; Warner TT; de Silva R; Lees AJ; Zetterberg H J Neurol Neurosurg Psychiatry; 2015 Nov; 86(11):1240-7. PubMed ID: 25589779 [TBL] [Abstract][Full Text] [Related]
7. Parkinson's disease and parkinsonism: Clinicopathological discrepancies on diagnosis in three patients. Toyoshima Y; Takahashi H; Katada S; Kojima N; Tada M; Tani T; Koike R; Nozawa T; Aida I; Nakajima T; Onodera O; Kakita A Neuropathology; 2021 Dec; 41(6):450-456. PubMed ID: 34779072 [TBL] [Abstract][Full Text] [Related]
8. Magnetic Susceptibility in Progressive Supranuclear Palsy Variants, Parkinson's Disease, and Corticobasal Syndrome. Satoh R; Weigand SD; Pham NTT; Ali F; Arani A; Senjem ML; Jack CR; Whitwell JL; Josephs KA Mov Disord; 2023 Dec; 38(12):2282-2290. PubMed ID: 37772771 [TBL] [Abstract][Full Text] [Related]
9. Oligomeric α-synuclein and tau aggregates in NDEVs differentiate Parkinson's disease from atypical parkinsonisms. Meloni M; Agliardi C; Guerini FR; Zanzottera M; Bolognesi E; Picciolini S; Marano M; Magliozzi A; Di Fonzo A; Arighi A; Fenoglio C; Franco G; Arienti F; Saibene FL; Navarro J; Clerici M Neurobiol Dis; 2023 Jan; 176():105947. PubMed ID: 36481435 [TBL] [Abstract][Full Text] [Related]
10. Diffusion-weighted brain imaging study of patients with clinical diagnosis of corticobasal degeneration, progressive supranuclear palsy and Parkinson's disease. Rizzo G; Martinelli P; Manners D; Scaglione C; Tonon C; Cortelli P; Malucelli E; Capellari S; Testa C; Parchi P; Montagna P; Barbiroli B; Lodi R Brain; 2008 Oct; 131(Pt 10):2690-700. PubMed ID: 18819991 [TBL] [Abstract][Full Text] [Related]
12. Complement system changes in blood in Parkinson's disease and progressive Supranuclear Palsy/Corticobasal Syndrome. Khosousi S; Hye A; Velayudhan L; Bloth B; Tsitsi P; Markaki I; Svenningsson P Parkinsonism Relat Disord; 2023 Mar; 108():105313. PubMed ID: 36739794 [TBL] [Abstract][Full Text] [Related]
13. Phosphorylated α-Synuclein Deposits in Cutaneous Nerves of Early Parkinsonism. Nolano M; Caporaso G; Manganelli F; Stancanelli A; Borreca I; Mozzillo S; Tozza S; Dubbioso R; Iodice R; Vitale F; Koay S; Vichayanrat E; da Silva FV; Santoro L; Iodice V; Provitera V J Parkinsons Dis; 2022; 12(8):2453-2468. PubMed ID: 36373295 [TBL] [Abstract][Full Text] [Related]
14. Tau protein quantification in skin biopsies differentiates tauopathies from alpha-synucleinopathies. Vacchi E; Lazzarini E; Pinton S; Chiaro G; Disanto G; Marchi F; Robert T; Staedler C; Galati S; Gobbi C; Barile L; Kaelin-Lang A; Melli G Brain; 2022 Aug; 145(8):2755-2768. PubMed ID: 35485527 [TBL] [Abstract][Full Text] [Related]
15. CSF α-synuclein and UCH-L1 levels in Parkinson's disease and atypical parkinsonian disorders. Mondello S; Constantinescu R; Zetterberg H; Andreasson U; Holmberg B; Jeromin A Parkinsonism Relat Disord; 2014 Apr; 20(4):382-7. PubMed ID: 24507721 [TBL] [Abstract][Full Text] [Related]
16. Evaluation of α-synuclein in CNS-originating extracellular vesicles for Parkinsonian disorders: A systematic review and meta-analysis. Taha HB; Ati SS CNS Neurosci Ther; 2023 Dec; 29(12):3741-3755. PubMed ID: 37416941 [TBL] [Abstract][Full Text] [Related]